Physician profile
Ryan G Scott
NPI 1487679528
$10,798.65
in general payments reported to CMS, 2019-2025
64 companies · $2,169 in 2025
The $2,169 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $724 · 2021: $1,167 · 2022: $1,584 · 2023: $2,073 · 2024: $2,249 · 2025: $2,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,372 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,371.99 |
| Education | $118.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,791.98 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $1,405.27 | 2019-2025 | |
| Novo Nordisk INC | $771.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $657.77 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Astrazeneca Pharmaceuticals LP | $572.32 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $549.53 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $487.93 | 2019-2025 | Eliquis, Camzyos |
| Otsuka America Pharmaceutical, INC. | $372.52 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $311.55 | 2019-2025 | Veozah, Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $253.82 | 2022-2025 | |
| Amgen INC. | $241.88 | 2019-2024 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $224.08 | 2022 | |
| Abbott Laboratories | $220.30 | 2022-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $214.86 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $214.23 | 2021-2023 | Qelbree |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.